HF2482

Purpose of the Bill

This bill aims to modify how changes in prior authorization clinical criteria and utilization review provisions are applied within the health care system in Minnesota. Specifically, it addresses the timing and conditions under which these changes affect health service coverage.

Main Provisions

• Postponing Changes: If a utilization review organization changes coverage terms or clinical criteria for a health care service within a plan or calendar year, these changes will not apply until the next plan year or calendar year. This rule protects patients who have already received prior authorization based on the existing criteria.

• Exceptions to Postponement:

  • The aforementioned postponement does not apply if the U.S. Food and Drug Administration (FDA) deems a drug or device unsafe or if it is withdrawn by the manufacturer or FDA.
  • It also does not apply if an independent source recommends changes in service usage for reasons of patient harm. This specific exception is subject to expire on December 31, 2025, but will continue under conditions of previously unknown and imminent patient harm beginning January 1, 2026.
  • Additionally, changes are allowed if a brand-name drug is removed from a formulary and replaced with a therapeutically equivalent generic or multisource brand-name drug at a lower cost, provided certain notifications are given.

• Notification Requirements: Utilization review organizations must provide a 60-day notice to prescribers, pharmacists, and affected enrollees when removing or changing the category of a brand-name drug.

Significant Changes to Existing Law

• The bill amends the Minnesota Statutes to specify how and when utilization review changes apply, introducing clear guidelines and exceptions.
• From January 1, 2026, specific provisions of chapter 62M will apply to the state's human services commissioner, ensuring consistency in how services are delivered under the MinnesotaCare and Medicaid programs (chapters 256B and 256L).

Relevant Terms

prior authorization, clinical criteria, utilization review, health care service, coverage terms, FDA, drug safety, formulary, generic drug, brand-name drug, MinnesotaCare, Medicaid, patient harm.